CONTRAD SWISS
Michele Fasola is an experienced professional in medical marketing and affairs, currently serving as Medical Marketing Manager at CONTRAD SWISS since October 2024. Prior to this, Michele held the position of Senior Medical Affairs Manager at IBSA Group from July 2008 to October 2024, focusing on osteoarthritis and pain/inflammation. Prior roles include Medical Marketing Manager at Helsinn Group, where responsibilities encompassed training affiliates and distributors, overseeing international congresses, and preparing medical support materials, and Sales Scientific Support at Milupa in the baby food market. Michele began the career as Product Manager at Istituto Sieroterapico Berna, specializing in vaccines and immunization. Educational background comprises a degree in Biology with a focus on Virology from Università degli Studi di Milano.
This person is not in any teams
CONTRAD SWISS
CONTRAD SWISS is a dynamic Swiss-based pharmaceutical corporation revolutionizing the regenerative medicine landscape. Headquartered in Lugano, Contrad Swiss is the owner of proprietary SIGMOLECS® Technology which takes the current use of peptides as active ingredients a giant step forward. The company portfolio comprises medical devices and aesthetic products, positioned in the premium segment, delivering unparalleled value. SIGMOLECS® is a unique technology guiding cell behaviour for a wide range of treatments. It talks to cells in their own language, enabling more effective therapies. It is designed to work with various treatment methods, following the body's natural systems and also enhancing the penetration of other important molecules. This breakthrough technology, utilizing customized peptide sequences, is the driving force behind our specialized non-invasive product lines in Orthopaedics (500Line), Aesthetic Medicine (ACTV8 PRO), and in our targeted alleviating lotion (Egyfil), all supported by recently published peer-reviewed studies. The 500Line, powered by SIGMOLECS®, addresses unmet clinical needs in osteoarthritis and connective tissue pathology through non-invasive, rapid-acting formulations. Egyfil offers targeted relief for muscle & joint stiffness and discomfort. ACTV8 PRO is designed for regenerative aesthetic physicians. CONTRAD SWISS is signaling the future of regenerative medicine.